H1N1 2009 Influenza, Influenza
Conditions
Keywords
vaccine, H1N1, influenza, H1N1 influenza vaccine, influenza vaccine, seasonal Influenza
Brief summary
The purpose of this study is to assess the safety and effectiveness (immune response) to a licensed H1N12009 influenza vaccine in adults when given at the same time or prior to the seasonal influenza vaccine. The study will enroll 300 adults (ages 20-59 years). Participants will be randomized into 2 groups. One group will receive one dose of a licensed H1N1 vaccine and one dose of the seasonal influenza vaccine at the same time; the second group will receive the seasonal influenza vaccine 3 weeks after receiving the licensed H1N12009 influenza vaccine. Study procedures include: medical history, blood samples and completing a memory aid. Participants will be involved in study related procedures for approximately 3-6 weeks depending upon the group assignment.
Detailed description
The objectives of this study are two-fold: 1. To evaluate the safety and immunogenicity of H1N12009 influenza vaccine in a convenience sample of adults, soon after the pandemic vaccine becomes available so as to inform the subsequent use of vaccine in public programs. 2. To evaluate the compatibility of co-administered H1N12009 pandemic vaccine and seasonal TIV vaccine in the same group of subjects, as the option of co-administration would be useful for public programs.
Interventions
Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently
Sponsors
Study design
Eligibility
Inclusion criteria
* Written informed consent * Adults 20-59 years of age
Exclusion criteria
* Allergies to eggs, thimerosal, gentamicin sulphate, neomycin * Life-threatening reaction to previous Flu vaccine * Bleeding disorder * Pregnancy * Receipt of blood or blood products in past 3 months * Chronic illness * Compromised immune system * Previous lab-confirmed H1N12009 infection * Receipt of H1N12009 vaccine * Receipt of Seasonal Influenza vaccine since March 2009
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of adverse events (AEs) for days 0-6 after each vaccination | Day 7 and Day 21 post vaccination |
| Occurrence of serious adverse events (SAEs) and other significant health events up to 21 days after each vaccination | Day 7 and Day 21 post vaccination |
Secondary
| Measure | Time frame |
|---|---|
| Immunogenicity: Comparison of baseline and post-immunization antibody titres | Day 21 post vaccination |
Countries
Canada